Daily Respiratory Research Analysis
Analyzed 257 papers and selected 3 impactful papers.
Summary
Analyzed 257 papers and selected 3 impactful articles.
Selected Articles
1. Biologic therapies targeting type 2 inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials.
Across seven RCTs, type 2 pathway biologics reduced moderate/severe COPD exacerbations by 23% versus placebo, with modest FEV1 (+43 mL) and SGRQ improvements and no excess serious adverse events. Benefits were most consistent for IL-4/IL-13 inhibition in patients with blood eosinophils ≥300/µL, supporting biomarker-guided biologic use.
Impact: Provides quantitative, trial-based evidence that biologics can reduce COPD exacerbations in biomarker-selected patients, clarifying a rapidly evolving therapeutic area.
Clinical Implications: Consider biologics targeting IL-4/IL-13 or IL-5 pathways in COPD patients with T2 inflammation (e.g., blood eosinophils ≥300/µL) to reduce exacerbations; avoid routine use in unselected COPD populations.
Key Findings
- Pooled rate ratio for moderate/severe exacerbations was 0.77 (95% CI 0.72–0.83).
- FEV1 improved by a pooled mean of 43 mL (95% CI 12.5–73.6).
- SGRQ total score improved by −2.46 units (95% CI −3.43 to −1.49).
- Greatest exacerbation reduction with IL-4/IL-13 blockade in patients with blood eosinophils ≥300/µL.
- No significant increase in serious adverse events compared with placebo.
Methodological Strengths
- Focused on randomized controlled trials with Cochrane RoB 2 bias assessment
- Random-effects meta-analysis with prespecified clinical endpoints and subgroup analyses
Limitations
- Heterogeneity in T2 enrichment strategies and patient selection across trials
- Modest heterogeneity for FEV1 and limited duration of controlled follow-up
Future Directions: Head-to-head trials and standardized biomarker thresholds are needed; long-term safety and cost-effectiveness should be evaluated in real-world T2-enriched COPD populations.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and a subset of patients exhibits type 2 (T2) inflammation. Biologic therapies targeting T2 inflammatory pathways have been evaluated in COPD, but their clinical efficacy remains variable. We performed a systematic review and meta-analysis to assess the efficacy and safety of biologic therapies targeting T2 inflammation in COPD. METHODS: Randomised controlled trials evaluating biologic therapies targeting interleukin (IL)-5, IL-5 receptor α, IL-4/IL-13 or thymic stromal lymphopoietin in patients with COPD and biomarker-defined T2 inflammation were systematically identified. Outcomes included moderate or severe COPD exacerbations, lung function (forced expiratory volume in 1 s (FEV₁)), health-related quality of life assessed by the St George's Respiratory Questionnaire (SGRQ) and serious adverse events. Random-effects meta-analyses were conducted when at least two comparable studies were available. Risk of bias was assessed using the Cochrane Risk-of-Bias 2 tool. RESULTS: Seven randomised controlled trials were included in the quantitative synthesis. Biologic therapies targeting T2 inflammation significantly reduced the rate of moderate or severe COPD exacerbations compared with placebo (rate ratio 0.77, 95% CI 0.72 to 0.83; p<0.001; I²=0%). Lung function improved modestly with a pooled increase in FEV₁ of 43 mL (95% CI 12.5 to 73.6; p=0.006; I²=55.3%). SGRQ total scores improved by -2.46 units (95% CI -3.43 to -1.49; p<0.001; I²=0%). Subgroup analyses showed the greatest reduction in exacerbations with IL-4/IL-13-targeting therapy in patients with blood eosinophil counts ≥300 cells/µL. No significant increase in serious adverse events was observed. CONCLUSIONS: Biologic therapies targeting T2 inflammation improve clinical outcomes in certain patients with COPD. The most consistent improvements were observed in studies that focused on inhibiting the IL-4/IL-13 pathway. However, variations in patient selection and in T2 enrichment strategies across trials make direct comparisons challenging. These results favour a biomarker-based, personalised approach over the routine use of biologics in unselected populations with COPD.
2. Impact of ultra-low tidal volume ventilation on 1-year functional outcome in COVID-19 ARDS patients. A long-term follow-up analysis of a randomized controlled trial.
In the VT4COVID multicenter RCT (n=215), ULTV did not reduce 1-year mortality versus conventional low tidal volume but was linked to a small yet significant decline in cognitive status at day 365, potentially related to higher PaCO2 exposure. These long-term data caution against indiscriminate use of ULTV in ARDS.
Impact: First randomized long-term follow-up to link ultra-low tidal volumes to worse cognitive outcomes without survival benefit, informing ventilator strategy trade-offs.
Clinical Implications: Prioritize avoidance of excessive hypercapnia when targeting ultra-low tidal volumes in ARDS; balance lung-protective aims with neurocognitive risk and consider individualized PaCO2 targets.
Key Findings
- No significant difference in 365-day mortality between ULTV and LTV groups (47/102 vs. 44/106).
- ULTV was associated with a small but significant decline in cognitive status at 1 year.
- Open-label, multicenter RCT with prospective registration (NCT04349618).
Methodological Strengths
- Multicenter randomized controlled design with 1-year follow-up
- Prospective trial registration and predefined outcomes
Limitations
- Open-label design may introduce performance bias
- COVID-19-specific ARDS limits generalizability; some missing outcome data among survivors
Future Directions: Evaluate neurocognitive outcomes of ventilator strategies across ARDS etiologies; test protocols that limit hypercapnia while maintaining lung protection.
BACKGROUND: Ultra-low tidal volume ventilation (ULTV) aims to minimize ventilator-induced lung injury in acute respiratory distress syndrome (ARDS), but is associated with an increase in arterial carbon dioxide (PaCO METHODS: VT4COVID was an open-label multicenter randomized controlled superiority trial performed in ten French intensive care units. Eligible patients were COVID-19 ARDS patients with arterial oxygen pressure (PaO RESULTS: Two hundred and fifteen patients were randomized to ULTV (n = 106) or LTV (n = 109) between April,2020 and April,2021. Seven patients were lost to follow-up and 34 surviving patients had missing data for at least one score. Mortality at day-365 was not significantly different between ULTV and LTV arms (47/102 [46%] vs. 44/106 [42%], hazard ratio 1.19 (95% confidence interval (CI CONCLUSIONS: ULTV is associated with a small but significant decrease in cognitive status at day-365 possibly related to exposure to higher PaCO TRIAL REGISTRATION: The trial was prospectively registered with ClinicalTrials.gov (NCT04349618) on April 16, 2020.
3. Respiratory viruses activate autophagy via the IFN-STAT1/STAT5B-SOCS1 axis.
The study demonstrates that interferons activate autophagy through a STAT1/STAT5B-driven upregulation of SOCS1 and that this autophagy is exploited by autophagy‑dependent respiratory viruses such as measles virus and RSV. Pharmacologic STAT5 inhibition uncouples IFN‑stimulated gene induction from autophagy, reducing virus‑induced autophagy and viral replication without broadly suppressing antiviral ISGs.
Impact: It uncovers a targetable host pathway that links IFN signaling to autophagy and demonstrates a strategy to inhibit autophagy‑dependent respiratory viruses without compromising innate antiviral programs.
Clinical Implications: Selective STAT5 modulation could be explored as a host-directed antiviral approach for autophagy‑dependent viruses (e.g., RSV), potentially complementing direct‑acting antivirals while preserving innate ISG responses.
Key Findings
- Interferons I/II/III robustly activate autophagic flux via JAK1‑3 and require both STAT1 and STAT5B.
- SOCS1 is a critical STAT1/STAT5B‑regulated effector that drives IFN‑induced autophagy; SOCS1 overexpression stimulates and its depletion impairs autophagy.
- STAT5 inhibition decouples ISG induction from autophagy, reducing autophagy‑dependent replication of measles virus and RSV without broadly suppressing antiviral ISGs.
Methodological Strengths
- Use of multiple IFN types, cell lines, and primary human lung fibroblasts with convergent results
- Integrated transcriptomics with genetic and pharmacologic perturbations of STAT factors and SOCS1
Limitations
- Predominantly in vitro models; absence of in vivo validation
- Potential off‑target effects of STAT5 inhibition and long‑term host impact were not assessed
Future Directions: Evaluate in vivo efficacy and safety of STAT5‑targeted modulation in autophagy‑dependent respiratory virus models and assess combinatorial strategies with direct‑acting antivirals.
Autophagy is an ancient catabolic process that has emerged as part of innate immunity. Upon infection, autophagy is activated but the key factors responsible remained unclear. Here, we show that interferon (IFN) released during viral infections subsequently activates autophagy via STAT1/5B-mediated upregulation of Suppressor of Cytokine Signaling 1 (SOCS1). Our data show that scavenging of IFNs diminishes autophagy induced by several respiratory viruses. All types of IFN (I, II and III) mediated robust autophagic flux activation in both cell lines and primary human lung fibroblasts in a JAK1-3 dependent manner. Depletion or pharmacological inhibition of individual signal transducer and activator of transcription (STAT) transcription factors demonstrated that both STAT1 and STAT5B are required for IFN-induced autophagy. Upon IFN stimulation STAT1 and STAT5B associate and translocate to the nucleus. Transcriptome analyses revealed that most known anti-viral IFN-stimulated genes (ISGs) remain induced to high levels upon inhibition of STAT5 expect for a small subset of ISGs, among them SOCS1. Overexpression of SOCS1 stimulated autophagy, whereas its depletion impaired IFN-induced autophagy. Successful viruses like measles virus (MeV) or respiratory syncytial virus (RSV) evolved strategies to exploit autophagy to promote their own replication. Uncoupling IFN-mediated ISG defenses from autophagy induction by STAT5 inhibition reduced virus-induced autophagy, and inhibited efficient replication of autophagy-dependent MeV and RSV. Overexpression of SOCS1 upon STAT5 inhibition largely rescued both infection-induced autophagy and viral replication. Taken together, our data show that IFN promotes autophagy via STAT1/STAT5B-SOCS1 in viral infections and reveal that targeting of this axis allows inhibition of autophagy-dependent viruses without compromising innate immune defenses.